Related Experiment Video
Updated: Jan 21, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Adalimumab - Safe and Effective Therapy for an Adolescent Patient with Severe Psoriasis and Immune Thrombocytopenia
Mariusz Sikora1, Patrycja Gajda, Magdalena Chrabąszcz
1Mariusz Sikora, MD, PhD, Department of Dermatology Medical University of Warsaw, Koszykowa 82A 02-008, Warsaw Poland; msikora@wum.edu.pl.
Abstract:
Psoriasis has been linked to several comorbidities, including metabolic syndrome, atopy, and celiac disease. However, the association between immune thrombocytopenia and psoriasis has rarely been described. We report the case of an adolescent with severe psoriasis and concomitant immune thrombocytopenia who obtained remission during treatment with adalimumab. Increased concentration of tumor necrosis factor-α seems to be a pathogenic linkage and therapeutic target for both diseases.
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Cognitive Development During Adolescence
What is the Immune System?
Gene Therapy
Guidelines and Strategies for Safe Computer Charting
Maintain Confidentiality and Security:
Revisionist Views of Adolescent and Adult Cognition

